Clinical Trial Update: Long Term Evaluation of Safety and Efficacy of Tildrakizumab in Patients With Psoriatic Arthritis [Phase 3]

View source ↗

Summary

Phase 3 trial update evaluating long-term safety and efficacy of tildrakizumab in psoriatic arthritis; the study is ongoing but not currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriatic Arthritis

Drugs mentioned

• Ilumya (tildrakizumab)

Snippet

Sponsor: Sun Pharmaceutical Industries Limited | Conditions: Psoriatic Arthritis | Phase 3 | Status: ACTIVE_NOT_RECRUITING